Primary Article

Predictability of Response to Endocrine Ablation in Breast Cancer

Authors: WAYNE E. CRISS PhD, KIRBY I. BLAND MD, J. PATRICK O'LEARY MD

Abstract

Carcinoma of the breast remains the most common and most frequently lethal form of cancer in women. In far-advanced disease, endocrine manipulation remains the major modality of treatment. Recent advances have shown that approximately 40% of breast cancers contain estradiol receptors in their cytoplasm. The presence or absence of these receptors is a good indicator of whether or not the patient will respond to endocrine ablation.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References